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ABSTRACT
Clinical cases of neonatal listeriosis are associated with brain disease and fetal 
loss due to complications in early or late pregnancy, which suggests that microglial 
function is altered. This is believed to be the first study to link microglial apoptosis 
with neonatal listeriosis and listeriosis-associated brain disease, and to propose a new 
nanovaccine formulation that reverses all effects of listeriosis and confers Listeria 
monocytogenes (LM)-specific immunity. We examined clinical cases of neonatal 
listeriosis in 2013–2015 and defined two useful prognostic immune biomarkers to 
design listeriosis vaccines: high anti-GAPDH1-22 titres and tumor necrosis factor (TNF)/
interleukin (IL)-6 ratios. Therefore, we developed a nanovaccine with gold glyco-
nanoparticles conjugated to LM peptide 1-22 of GAPDH (Lmo2459), GNP-GAPDH1-22 
nanovaccines formulated with a pro-inflammatory Toll-like receptor 2/4-targeted 
adjuvant. Neonates born to non-vaccinated pregnant mice with listeriosis, showed 
brain and vascular diseases and significant microglial dysfunction by induction of 
TNF-α-mediated apoptosis. This programmed TNF-mediated suicide explains LM 
dissemination in brains and livers and blocks production of early pro-inflammatory 
cytokines such as IL-1β and interferon-α/β. In contrast, neonates born to GNP-
GAPDH1–22-vaccinated mothers before LM infection, did not develop listeriosis or brain 
diseases and had functional microglia. In nanovaccinated mothers, immune responses 
shifted towards Th1/IL-12 pro-inflammatory cytokine profiles and high production of 
anti-GAPDH1–22 antibodies, suggesting good induction of LM-specific memory.
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BACKGROUND
Cerebral listeriosis caused by the human pathogen 
Listeria monocytogenes (LM) constitutes a severe disease 
in infants and elderly people, with a mortality rate of 30% 
[1]. LM targets the central nervous system (CNS) and 
foetus, and the most common listeriosis-related diseases 
are meningitis, meningoencephalitis, brain abscesses, 
foetal malformations and septicaemia [2-4]. Since 2008, 
the cases of listeriosis have increased in the European 
Union, but especially in Spain, where listeriosis cases 
reported between 2008 and 2014 are 1.15 cases per 
100,000 inhabitants [5-7]. However, the landscape can 
be worse as listeriosis has only been listed as a notifiable 
disease in Spain since March 2015 [8], and therefore, 
annual incidences may be higher. Despite the amassing 
epidemiological data on listeriosis, immunological 
biomarkers were not investigated till recently [9]. 
Moreover, a vaccine that prevents neonatal listeriosis and 
avoid or at least diminish brain diseases and foetal injury 
is not yet available but necessary. Our group has been 
preparing vaccines for systemic listeriosis in experimental 
models with good success. Dendritic cells (DCs) loaded 
with two LM immunodominant peptides, peptide 91-99 
of listeriolysin O virulence factor, LLO91-99 and peptide 
1-22 of glyceraldehyde-3-phosphate dehydrogenase 
(Lmo2459), GAPDH1-22 [10-12] or phagosomes obtained 
from macrophages and containing live wild type LM 
(LMWT) [13], prevented systemic listeriosis in mice. 
However, none of these vaccine vectors appeared suitable 
for neonatal listeriosis, because phagosomes containing 
live LMWT, supposed a risk for pregnant mothers, as they 
may develop listeriosis. Moreover, DCs poorly crossed the 
placenta and blood-brain barriers as a putative strategy to 
avoid injuring the foetus or causing neuroinflammation 
[14, 15]. 
Microglia (MG) are resident macrophages that 
survey the brain parenchyma to repair any damage, control 
pathogen invasion and prevent neuron injury. Therefore, 
they are responsible for controlling LM infection and 
potential target cells to combat listeriosis in the brain of 
humans, mice or ruminants [16-19].
Similar to macrophages, MG are divided into 
M1 and M2 subsets depending on their pro- or anti-
inflammatory cytokine pattern and similar to macrophages 
[20-24]. In this regard, pro-inflammatory M1 macrophages 
or MG are microbicidal phagocytes and antigen-presenting 
cells (APC) that produce soluble and neurotoxic 
inflammatory mediators such as tumour-necrosis factor 
(TNF)-α, IL-1β, IL-12, NO or type I interferon (IFN-
α/β) [20]. However, continuous activation of M1 subset 
of MG might disrupt the delicate balance in the CNS 
and have a negative effect on neuronal survival [20, 24]. 
Upon microbial infection, M1 macrophages also induce 
programmed cell death, such as necrotic-programmed cell 
death, TNF-mediated apoptosis or pyroptosis [25-28]. In 
fact, apoptosis may be understood as a host mechanism to 
control infection [28] or a virulence process to spread the 
pathogen [29]. M2 subset of MG parallel the alternative 
activation pattern of macrophages and showed high 
levels of IL-6 and IL-10; activation of pro-inflammatory 
negative regulators such as suppressor of cytokine 
signalling (Socs3); low phagocytic functions; promotion 
of immunoregulation and neuroprotection; and presented 
low production of reactive oxygen species [22-24].
The aims of this study were as follows. (1) To 
examine clinical cases of listeriosis to search for immune 
biomarkers to prepare safe nanovaccines. (2) To establish 
a neonatal cerebral listeriosis model in mice to investigate 
brain disease, biomarkers detected in human listeriosis 
cases, microglia function and apoptosis and bacterial 
virulence factors. (3) To test gold glyconanoparticle (GNP) 
vaccine formulations with adjuvants, that help to prevent 
listeriosis and brain-associated morbidities, including 
microglial dysfunction. 
RESULTS
Biomarkers of poor prognosis in neonatal 
listeriosis
To develop a clinical vaccine that prevented neonatal 
listeriosis, we explored cases of neonatal listeriosis in 
2013-2015 to obtain information about common diseases 
and immune markers of poor prognosis in the two 
health institutions participating in this study, Hospital 
Universitario Donostia (HUD) and Hospital Universitario 
Marqués de Valdecilla (HUMV). From a total of 13 
listeriosis cases in HUD, three cases corresponded to 
neonatal listeriosis due to complications during pregnancy, 
a case in the first trimester causing an abortion (HUD003 
patient in Figure 1A) and two cases at late gestational 
period, one neonate born with severe meningitis and 
treated for a month with ampicillin (HUD008 patient is the 
neonate of HUD007 patient) and a patient with caesarean 
of twins and first twin born healthy, while the second twin 
died (HUD004 patients). Therefore, neonatal listeriosis 
cases presented with a 50% mortality rate. While neonates 
with listeriosis presented severe brain diseases, mothers 
only presented small diarrhea or fever. In the same period, 
we also had an adult patient with listeriosis who died from 
lung adenocarcinoma and bacteraemia (HUD005), and 
served as a positive control for poor listeriosis prognosis 
(Figure 1A). High virulence of clinical isolates from 
listeriosis patients appeared to correlate with prognosis, 
as clinical isolates from mothers with neonatal listeriosis 
(HUD003, HUD004, HUD007 and HUD008) had 2-10 
times higher virulence (LD50) than standard LM strains 
such as 10403S in C57BL/6 congenic mice; a model that 
is highly resistant to LM infection. A clinical isolate from 
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Figure 1: Clinical manifestations and biomarkers of patients with neonatal listeriosis. A. Clinical manifestations and 
treatments of patients with listeriosis during 2013-2015. aPatients identified by internal codes. HUD: Hospital Universitario de Donostia 
(Gipuzkoa). NT, no treatment. bVirulence of clinical bacterial isolates (LD50). Genotyping and serotyping were measured via PCR multiplex 
and sequence types (ST) were determined using MLST [5]. Spleens of C57BL/6 mice infected with 5000 CFU/mL of LM isolates from 
patients were recovered after 72 h and examined for CFU/mL. We recovered 250 CFU/mL in the spleens of mice infected with 10403S 
LM strain and 240 CFU/mL in mice infected with EGD strain (these were controls of virulence). cSera of listeriosis patients were examined 
for peptide ELISA using GAPDH1-22 peptides or LLO189-201 peptides. Results are presented as OD and mean ± SD values of triplicate 
experiments. Anti-LLO189-201 titers were <0.2 ± 0.03 OD units and therefore non-significant, except for patient HUD003 with 0.4 ± 0.05 OD 
units. Negative controls correspond to levels observed in sera of healthy donors (controls). B. PBMCs (CD45+) of patients with listeriosis 
were stained with different antibodies to label cell surface markers. Cells were analysed by FACS. Results are expressed as mean ± SD 
percentages of positive cells. Controls correspond to the percentages obtained in healthy donors (controls). C. Levels of pro-inflammatory 
cytokines in sera of listeriosis patients analysed by flow cytometry. Results are expressed as the mean ± SD concentration (pg/mL) of three 
independent experiments. Controls correspond to levels detected in sera of healthy donors (control). ANOVA was applied to cytokine 
results. *P ≤ 0.05, **P ≤ 0.01.
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the deceased patient (HUD005) had 200-fold higher LD50. 
Mice infected with standard 10403S LM strain served 
as controls of virulence (data in Figure legend). Other 
reported biomarkers of poor prognosis in sera of adult 
listeriosis patients [9] are: (1) low levels of antibodies 
against immunogenic LM virulence factors such as 
GAPDH (GAPDH1-22 epitope) or listeriolysin O (LLO189-201 
epitope). Negative controls correspond to healthy donors 
where antibody titres were considered basal levels. (2) 
The imbalance in the cell populations among peripheral 
blood mononuclear cells (PBMCs) or whole blood cells 
(Figure 1B), such as high percentage of granulocytes 
(CD66b+) and low percentage of monocytes (CD14+) or 
CD8+ or CD4+ T lymphocytes (patient HUD005, Figure 
1B). Patients with neonatal listeriosis presented with high 
titres of anti-GAPDH1-22 and undetectable anti-LLO189-201 
antibodies, normal percentages of monocytes and CD8+ 
T cells, and higher numbers of mature and immature 
granulocytes as a result of bacterial infection (Figure 
1B). A predominant Th2 cytokine profile with low Th1-
Th17/IL-6 ratios, is also a biomarker of poor prognosis in 
adult listeriosis because it favours bacterial growth [1, 3, 
4, 9]. We observed that neonatal listeriosis patients also 
presented low TNF-α/IL-6 ratios, indicating predominant 
Th2 immune responses (Figure 1C). Controls of cytokine 
measurements correspond to healthy donors (controls in 
Figure 1C). Patients with neonatal listeriosis presented 
some biomarkers of poor prognosis, such as hypervirulent 
LM strains and low ratios of TNF-α/IL-6, as well as 
some biomarkers of better prognosis, such as high titres 
of anti-GAPDH1-22 antibodies and normal percentages of 
monocytes and CD8+ T cells. This indicates that efforts 
Table 1: Listeriosis profile in neonates, pregnant and non-pregnant female mice.
Organs (mice type)a CFU/mLb
bMicroglia (LMWT) 6.2 x 103 ± 0.1
bMicroglia (LM∆LLO) 0 ± 0
bMicroglia (LM∆ActA) 3.5 ± 0.1*
Liver (NP-LMWT) 9.9 x 103 ± 0.2
Liver (Mo-LMWT) 2.48 x 104 ± 0.2
Liver (Mo-LM∆LLO) 0 ± 0.1
Liver (Mo-LM∆ActA) 3.4 x 102 ± 0.1
Spleen (NP-LMWT) 8.5 x 101 ± 0.1
Spleen (Mo-LMWT) 6.5 x 101 ± 0.1
Spleen (Mo-LM∆LLO) 0 ± 0
Spleen (Mo-LM∆ActA) 4.3 ± 0.1*
aP4 neonates born to LMWT-, LM∆LLO- or LM∆ActA-infected mothers were killed and microglia were isolated from brains, 
homogenized and plated on brain–heart infusion (BHI) agar. Mothers were also killed (Mo-LMWT) as well as non-pregnant 
female mice infected with LMWT (NP-LMWT), and livers and spleens were homogenized and plated on BHI agar. Results are 
expressed as CFU/mL. bResults are expressed as CFU/mL. (P < 0.5), (*P < 0.1)
Table 2: Immune markers expression in microglia of mice neonatesa.
bMicroglia-NI Microglia-LMWT
CD11b 85 ± 0.7 8.2 ± 0.2
F4/80 35 ± 0.2 17.5 ± 0.5
MHC-II 53.7 ± 0.4 43.1 ± 0.5
MHC-I 98.1 ± 0.2 67 ± 0.2
CD14 20.5 ± 0.5 3.9 ± 0.1
CD11c 31 ± 0.08* 6.3 ± 0.2
CD86 27 ± 0.3 2 ± 0.08*
Annexin V 2.1 ± 0.2 24.6 ± 0.6
aMicroglia isolated from P4 neonates born to either LMWT-infected (Microglia-LMWT) or bNI (Microglia-NI) mothers were 
surface stained for the following markers: CD11b-FITC, F4/80-PE, MHC-II-APC, MHC-I-APC, CD14-PE and CD86-V450. 
Samples were acquired using a FACSCanto flow cytometer and percentages of positive cells for each antibody are shown. 
Results are expressed as the mean ± SD of triplicate experiments (P < 0.5), *(P < 0.1).
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Figure 2: Brain disease in neonatal listeriosis depended on actA and hly genes of the pathogen. A. P0 neonates born to 
GFP-LMWT-, GFP-LM∆LLO- and GFP-LM∆ActA-infected or NI mothers. B. Comparison of P4 neonates from Panel A for physical and skin 
appearance and motility. C. Clinical tests performed in P4 neonates: movement test, skin test, length, weight and metrics. Results are the 
mean ± SD of three different experiments. *Bars correspond to 0.1 ± 0.01 cm. **Bars correspond to 0.5-1 melanoblasts/mm of skin. D. 
Brains isolated from P4 neonates of LMWT-, LM∆LLO- and LM∆ActA-infected or NI mothers. Upper images show the fragility of brain covering 
in P4 neonates born to LMWT-infected mothers. 
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should be concentrated on shifting from Th2 to Th1 
cytokine profiles to decrease the risk of listeriosis in 
pregnant women.
Brain disease in neonatal listeriosis depended on 
actA and hly genes, while microglial targeting 
depended on actA gene
We developed a mouse model of neonatal listeriosis 
to evaluate brain disease and biomarkers detected in 
humans, exploring also putative bacterial virulence factors. 
Adult listeriosis has a 30% mortality rate, and in neonatal 
listeriosis, meningitis, encephalitis and cerebritis are the 
main brain diseases, which have higher mortality rates [9, 
30-36]. We used five pregnant C57BL/6 female mice at 
16 days of embryonic gestation (E16) (n = 5), as a model 
of neonatal listeriosis and challenged them intravenously 
(i.v) or not (not infected; NI) with 3000 CFU/mL of wild-
type GFP-LMWT (LMWT), GFP-LM∆LLO (LM∆LLO) or GFP-
LM∆ActA (LM∆ActA) mutants that encode LLO and ActA 
virulence factors, respectively. Both virulence factors are 
involved in microglial infection in vitro [19]. At E20 we 
observed 3 ± 0.5 pups born to LMWT-infected mothers, 
4 ± 0.5 pups born to LM∆ActA-infected mothers, 8 ± 0.1 
pups born to LM∆LLO-infected mothers and 9 ± 0.2 pups 
born to NI mothers (Figure 2A, images correspond to a 
representative experiment out of three independent ones, 
P ≤ 0.05). This indicated a 66% mortality rate, which was 
higher than in humans because we did not treat infected 
mice with antibiotics. Only two P4 neonates born to 
LMWT-infected mothers survived (Figure 2B), while all 
other pups born to either LM∆LLO- or LM∆ActA-infected or 
NI mothers were alive (Figure 2B). We chose P4 neonates 
as they corresponded to age 1 month in human neonates; 
the period with antibiotic treatment in listeriosis and hair 
development in mice. These results suggest involvement 
of actA gene in foetal wastage as reported previously 
[30-32], which explains the lower number of neonates in 
mothers infected with LM∆ActA mutants. The lack of skin 
pigmentation was noticed only in P4 neonates born to 
LMWT-infected mothers. We investigated all P4 neonates 
for clinical data, weight, length, coordination movement 
tests and general observations with a magnifying lens 
before they were killed. Clinical data were normal in 
P4 neonates born to NI or LM∆LLO- or LM∆ActA-infected 
mothers (Figure 2C), although movement test performance 
was 30% reduced in the latter. P4 neonates born to LMWT-
infected mothers showed 50% weight loss, no ability 
to move in the metric paper test, and a low number of 
black hair bulbs per millimeter of skin (0.1 ± 0.01) with 
a wrinkled skin appearance (Figure 2B, 2C). The lack of 
coordinated movements and melanoblast migration to 
hair bulbs in P4 neonates born to LMWT-infected mothers, 
confirmed severe CNS retardation after the E16 embryonic 
stage [33, 34]. We also detected cerebritis or enlarged 
heads in P4 neonates born to LMWT-infected mothers 
(Figure 2B). We noticed softer cranial covering, lack of 
brain integrity and a significant reduction of cerebral blood 
vessels in P4 neonates born to LMWT-infected mothers 
(Figure 2D), which might explain their difficulties in 
moving and developmental delay. Cell counts in the 
brain indicated a severe 44% loss of cellularity in P4 
neonates born to LMWT-infected mothers, compared to 
normal cellularity in P4 neonates born to LM∆LLO- or 
LM∆ActA-infected mothers (3.96 × 106 compared with 9 
× 106 cells, Figure 2C). We conclude that the main brain 
disease, cerebritis, reduction of cerebral blood vessels 
and cellularity, lack of brain integrity, and melanoblast 
migration to the hair bulbs seemed to depend on actA and 
hly genes.
We investigated LM target cells in the brains of our 
neonatal listeriosis model, establishing mixed microglial 
cultures from the hippocampus (95% neurons and 2% 
microglial cells) of P4 neonates born to LMWT-infected 
mothers. We confirmed a large amount of GFP-LMWT 
(green fluorescence) localized almost exclusively in 
microglial cells labelled with the macrophage marker 
F4/80 (red fluorescence), while neurons stained for 
Table 3: Anti-inflammatory pattern of microglial cells from P4 neonates.
Activation pattern of Microgliaa IL-6a IL-10 TNF-α IL-1 IFN-α
CONTROL (NI-Mo) 3.0 ± .01 1.2±0.1 6.0 ±0.1 1.0± 0.1 1.1±0.2
LMWT (NI-Mo) 70.0± 0.2 19.0±0.1 1385±0.6 5.0±0.1 5.5 ± 0.3
LM∆ActA (NI-Mo) 18.4 ± 0.6 5.4±0.1 23.0±0.9 22.0±0.5 18.2 ± 0.8
LM∆LLO (NI-Mo) 12.0 ± 0.3 3.2±0.1 18.0±0.7 1.0±0.1 8.5 ± 0.2
LMWT 106± 0.2 16.0±0.1 1315±0.6 6.0±0.1 9.1 ± 0.3
LM∆ActA 13.8 ± 0.6 5.6±0.1 21.0±0.9 20.0±0.5 25.0 ± 0.8
LM∆LLO 14.0 ± 0.3 3.0±0.1 17.0±0.7 8.0±0.1 8.0 ± 0.2
aMicroglial cells from P4 neonates born to NI mothers (NI-Mo) and infected in vitro with different LM strains or born to 
LMWT, LM∆ActA or LM∆LLO infected mothers. Levels of pro-inflammatory cytokines were analysed using the CBA kit (Becton 
Dickinson) by flow cytometry. Microglial cells were infected for 20 min, incubated with 30 µg/mL gentamicin, and culture 
supernatants collected after 2 hour. All supernatants were filtered before storage at −80°C to remove bacteria from cytokine 
measurements. Results are expressed as the mean ± SD concentration (pg/mL) from three independent experiments (P ≤ 0.05).
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Figure 3: Neonatal listeriosis targets microglia and induces apoptosis. A. Confocal images of purified microglia containing 
GFP-LMWT showing that this pathogen has tropism for microglia. Left four images correspond to confocal microscopy images of microglia 
of neonates born to GFP-LMWT-infected mothers. Images of purified microglia containing GFP-LMWT showing that this pathogen has 
tropism for microglia. Actin filaments are labelled with TRITC-phalloidin and nuclei with 4’,6-diamidino-2-phenylindole (DAPI; blue 
fluorescence) (isolated microglia from P4-LMWT images). Right images labelled as P4-LMWT correspond to mixed microglial cultures 
showing that GFP-LMWT (green channel) invaded microglial cells labelled with F4/80-PE antibody (red channel), while surrounding 
neurons labelled with anti-tubulin β3 antibody (blue channel) did not show intracellular bacteria. Bars, 10 µm. B. Left plot represents 
the cell surface markers analysed by FACS from isolated microglia of P4 neonates born to NI mothers, and infected in vitro with LMWT, 
LM∆LLO or LM∆ActA at MOI of 10:1 (bacteria: cell). Results are expressed as the mean ± SD of percentages of positive cells (P ≤ 0.05). Right 
images represent isolated microglia of P4 neonates born to GFP-LMWT-infected (P4-LMWT) or NI (P4-NI) mothers and analysed by confocal 
microscopy using different markers, CD11b-APC (LMWT) or CD11b-FITC (NI), F4/80-PE and DAPI to stain nuclei. Co-localization of 
CD11b, GFP-LMWT and F4/80-PE fluorescence was detected as light yellow fluorescence (P4-LMWT images). C. Microglia as in Panel A 
were infected with LMWT, LM∆LLO or LM∆ActA for 20 min, washed and stained for annexin V-APC and 7-ADD. Results are expressed as the 
percentages of late apoptotic cells (Late-A, Q2-2 area corresponding to 7-ADD+ annexin V+ cells) and the percentages of early apoptotic 
cells (Early-A, Q4-2 area corresponding to annexin V+ 7-ADD− cells) (mean ± SD) (P ≤  0.05). 
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α-tubulin were not infected (blue fluorescence in 
microglial mixed cultures; Figure 3A). We verified LM 
viability in microglia of P4 neonates born to LMWT-
infected mothers and detected 6200 CFU/mL, which was 
20%-25% of total CFU of pregnant mothers (Table 1). 
We also followed listeriosis in pregnant mothers infected 
with LMWT and confirmed normal ability to clear LM 
infection. CFU/mg in the spleen were lower than in the 
liver and similar to those in non-pregnant female mice and 
LMWT-infected mothers (Table 1). In mice infected with 
103-fold less virulent LM∆ActA strain [31, 32], 3.5 CFU/
mg were detected in microglial cells. We also detected 
significant numbers of bacteria in the liver of LM∆ActA-
infected mothers (340 CFU) and 10-fold fewer bacteria 
in the spleen (Table 1). Neonates born to LM∆LLO-infected 
mothers showed no detectable bacteria in microglia, liver 
or spleen, which suggested these mutants did not cross 
the placental or brain barriers, while LM∆ActA mutants did 
(Table 1). Therefore, actA but not hly gene participated in 
microglial targeting.
Neonatal listeriosis induces an apoptotic cell 
surface phenotype in microglia
LM infection of phagocytes induces different 
types of apoptosis or necrosis and significant cell surface 
remodeling [27-29]. We investigated cell surface changes 
in the microglia of P4 neonates born to LMWT-infected 
mothers and focused on apoptotic markers. We detected 
lower percentages of CD11b+ (8.2% of positive cells), 
CD14+ (3.9% positive cells), CD11c+ (6.3% positive cells), 
CD86+ (2% of positive cells) and MHC-I+ (from 67%-
90% of positive cells), and normal percentages of MHC-
II+ (43.1% of total positive cells) compared to microglia 
of neonates born to NI mothers (Table 2). To confirm 
that LMWT infection was responsible for the reduced 
expression of cell surface markers, we obtained microglia 
from NI mothers and infected them with LMWT, LM∆LLO 
or LM∆ActA mutants at MOI of 10:1 (bacteria: cell) and 
analysed cell surface markers by flow cytometry (Figure 
3B). We confirmed significant reductions in CD11b+ 
(12% of positive cells), CD14+ (10% of positive cells) 
and CD86+ (2%-4% of positive cells) cell surface markers 
after microglial infection with LMWT, LM∆LLO or LM∆ActA 
mutants (Figure 3B). There were less prominent reductions 
in MHC-I+ after infection with LMWT or LM∆LLO and a 
greater reduction after infection with LM∆ActA mutants 
(53% of positive cells). Confocal microscopy of purified 
microglia of P4 neonates born to NI mothers showed high 
staining of intracellular and membrane-bound CD11b 
(Figure 3B). However, cell surface staining of CD11b 
decreased significantly in microglia of P4 neonates born 
to LMWT-infected mothers, appearing mainly intracellular 
(white fluorescence) and co-localizing with GFP-LMWT 
(green fluorescence) and F4/80 marker (red fluorescence) 
(Figure 3B). Co-localization of the three markers (white, 
green and red fluorescence) appeared as light yellow 
fluorescence (Figure 3B). We confirmed that LMWT 
induced an apoptotic phenotype in microglia following 
the levels of the classical apoptotic marker, annexin V, by 
flow cytometry. Microglia of P4 neonates born to LMWT-
infected mothers had 24.6% of cells with the apoptotic 
marker annexin V+, compared to only 2.1% in microglia 
of P4 neonates born to NI mothers (Table 2). To define 
the induction of apoptosis as early or late, we used a 
method that differentiates early and late apoptosis by 
fluorescence-activated cell sorting (FACS) as the double 
staining of cells with annexin V and 7-aminoactinomycin 
D (7-AAD) (late apoptosis) or single staining with annexin 
V (early apoptosis) in microglia of P4 neonates born to NI 
mothers and infected in vitro with different LM mutants. 
Microglial infection with LM∆LLO or LMWT induced early 
apoptosis in 9-12% of cells, annexin V+7-AAD−, (Figure 
3C). LM∆ActA infection of microglia failed to induce early 
apoptosis, since we only detected apoptosis in 1% of 
annexin V+7-AAD− cells, which was similar to 0.9% of 
annexin V+7-AAD− cells in control microglia (Figure 3C). 
We concluded that actA gene participated in LM induction 
of early apoptosis in microglia.
To establish whether LM induced pro- or anti-
inflammatory apoptosis in microglia, we measured the 
pattern of cytokine release by microglia of neonates born 
to NI mothers, and infected them with LMWT, LM∆LLO or 
LM∆ActA. Microglial infection with LMWT induced high 
levels of TNF-α and IL-6 and significant levels of IL-
10, but low levels of IL-1 or IFN (Table 3). However, 
microglial infection with LM∆ActA failed to produce 
significant levels of TNF-α IL-6 or IL-10 and induced low 
levels of IL-1 and IFN. Microglial infection with LM∆LLO 
only induced basal levels of most cytokines (Table 3). 
Similar cytokine patterns were observed in isolated 
microglia of P4 neonates born to LMWT-, LM∆ActA- or 
LM∆LLO-infected mothers (Table 3). We concluded that 
actA gene was relevant for LMWT-induced apoptosis in 
microglia, presenting a predominant Th2 cytokine pattern 
but with high levels of TNF-α. 
Characterization of the early transcriptional 
TNF-apoptotic program of microglia
We characterized the early apoptotic transcriptional 
program induced by LMWT in microglia by differential 
expression of genes included on the Affymetrix GeneChip 
MOE430A2.0. We infected microglia in vitro with 
LMWT, LM∆LLO or LM∆ActA for 20 min and normalized all 
values using levels of NI cells. Of the 162 genes in the 
first selection, we applied innate immunity functional 
clustering and identified 93 genes that were differentially 
expressed in LM-infected cells (Figure 4A). We reduced 
the innate immunity functional cluster to 32 genes 
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that were exclusively regulated by TNF-α (Figure 4B 
and Supplementary Table S1), which was the cytokine 
produced at highest levels after LMWT infection of 
microglia (Table 3). LMWT-infected microglia presented 
two early expression programs regulated by actA gene: 
induction of a TNF-α death-regulated program, and 
repression of a pro-inflammatory expression pattern 
involved in macrophage activation and antigen processing. 
The TNF-α-induced death signature, included the TNF-α 
receptor-associated component genes, tnf, traf3, tnfaip1 
or tnfrsf1b; the TLR-associated genes, tlr1, tlr2 and cd14; 
the NFKB signalling genes, nfkbia and nfkbiz; ant the 
mitogen-activated protein kinase (MAPK) gene, mapk1 
(Figures 4C and Supplementary Table S2); the early 
immune response gene, ier3; and two genes involved in 
ubiquitination, uba2 and uba3. Other genes belonging 
to this signature were the early immune response gene, 
irg1, cytokine gene il1b, the chemokine genes ccl3 and 
ccl5, the ion-pump ATPase regulatory gene atp6v1e1, 
and cathepsin genes ctsb, ctsd and ctsk, but with less 
intensity. The repressed pro-inflammatory signature in 
LMWT-infected microglia included the pi3kcg gene; the 
MHC I and pro-inflammatory h2-k1 gene implicated in 
antigen presentation; the lysosomal acid sphingomyelinase 
genes, smpd1 and scarb2, belonging to pro-inflammatory 
apoptotic and antigen-degradation routes; and the small 
GTPase component of cross-presentation signalling 
pathways, rab14 gene (Figures 4C and Supplementary 
Figure S1). Other genes belonging to this repressed pro-
inflammatory profile but with less intensity were the 
autophagy and inflammasome component, atg4b, and the 
SNARE component syntaxin 3, stx3. These results suggest 
a marked effect of LMWT infection in the transcriptome 
of microglia and the induction of TNF-α-mediated death 
signalling controlled by actA gene, which was different 
from the transcriptional pattern that LMwt induced in 
macrophages (Figure 4A).
Effect of pregnancy vaccination with GNP-
GAPDH1-22 nanovaccines formulated with the 
TLR2/TLR4 adjuvant, DIO-1, in neonatal 
listeriosis
Efficient vaccine vectors in listeriosis are expected 
to control pathogen dissemination to the CNS and liver, 
and release protective cytokines such as IL-12p40, while 
showing basal levels of acute anti-inflammatory cytokines 
such as IL-6 [10-12, 37-39]. In addition, vaccine vectors 
might ideally prevent microglial apoptosis that appears 
linked to brain-associated morbidity. We formulated 
GNP-GAPDH1-22 nanovaccines with DIO-1 as adjuvant 
that signals through TLR2 and TLR4, and induces IL-
12 without causing excessive inflammation or IL-10 
production [40]. Our purpose was to improve the spectrum 
of previous nanovaccine formulations with another 
adjuvant, Advax [39, 41] to prevent microglial dysfunction 
and brain disease in neonatal listeriosis. We vaccinated 
five pregnant mice at day 9 of gestation (E9), followed 
by challenge with LMWT on day 16 of gestation (E16) for 
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Figure 4: Characterization of early transcriptional program induced by LMWT in microglia. A. Heat map presentation of 
the 93 most differentially expressed genes of LM innate immunity cluster of bone-marrow macrophages (left) or microglia (right) infected 
with LMWT, LM∆LLO or LM∆ActA for 20 min or non-infected (NI). Coloured rows represent expression ratios from ≤ -2.0 Fold-change (FC)-
repressed genes in green to ≥ 2.0 FC-induced genes in red. Black boxes correspond to non-differentially expressed genes. B. Microglia 
from P4 neonates born to NI mothers were infected with LMWT, LM∆LLO or LM∆ActA for 20 min or non-infected (NT), RNA was isolated and 
differential microarrays performed. Heat map presentation of the 32 most differentially expressed genes of LM innate immunity cluster. 
Coloured rows represent expression ratios from ≤ -2.0 Fold-change (FC)-repressed genes in green to ≥ 2.0 FC-induced genes in red. Black 
boxes correspond to non-differentially-expressed genes. C. Bioinformatic analysis of actA related genes overexpressed in LMWT-infected 
microglia (upper plots) that correspond to tnf, nf-kb, cd14 and mapk1 signalling genes. Genes related with actA and repressed in LMWT-
infected microglial cells (lower plots) that correspond to pi3Kcg, h-2k, smpd1 and rab14 antigen processing trafficking. 
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3 days. We observed a lack of viable CFU/mL in brains 
and only 20-25 viable CFU/mL in the liver of P4 neonates 
born to GNP-GAPDH1-22-vaccinated mothers, indicating 
high efficacy to block LMWT dissemination in neonates 
(Figure 5A). P4 neonates born to non-vaccinated (NV) 
mothers and infected with LM∆ActA mutants (n = 5) showed 
10-12 viable CFU/mL in brains but 3600 viable CFU/mL 
in the liver, indicating that these mutants disseminated 
in high numbers in the liver, severely crippled in their 
ability to invade the brain (Figure 5A). P4 neonates born 
to NV mothers and infected with LMWT (n = 5) showed 
7000 viable CFU/mL in the brain and 5800 viable CFU/
mL in the liver, indicating high dissemination of bacteria 
in both organs (Figure 5A). The high efficiency of GNP-
GAPDH1-22 nanovaccines to prevent dissemination in the 
brain and liver prompted us to focus on these vaccine 
vectors to prevent other listeriosis-associated morbidity. 
P4 neonates born to GNP-GAPDH1-22-vaccinated mothers 
and challenged with LMWT showed normal ability to 
move (movement test), normal numbers of hair follicles 
(skin test), as well as normal weight and length compared 
to control neonates (Figure 5B). All these parameters 
were impaired in P4 neonates born to NV mothers and 
infected with LMWT (Figure 5B). Isolated microglia of P4 
neonates born to GNP-GAPDH1-22-vaccinated mothers 
also prevented early and late microglial apoptosis (Figure 
5B) and shifted microglial cytokine production towards a 
Th1 pattern with high levels of IL-12p40 and high ratios 
of TNF-α/IL-6 (Table 4). We also detected high titres of 
anti-GAPDH1-22 antibodies in sera of GNP-GAPDH1-22-
vaccinated mothers (GNP-GAPDH1-22 + LM
WT) (Table 
4), which is another indicator of vaccine efficiency in 
listeriosis [10, 39]. Microglia of P4 neonates born to NV 
and LMWT-infected mothers presented high levels of IL-
6, IL-10 and TNF-α and lacked production of IL-12p40 
(Table 4); a Th2 pattern similar to the cytokine profile 
reported in meningitis and encephalitic cases of listeriosis 
[4, 33, 35]. We also detected low titres of anti-GAPDH1-22 
antibodies in sera of NV mothers and infected with LMWT 
or LM∆ActA, suggesting low induction of specific immune 
responses (Table 4). Similarly, microglia of P4 neonates 
born to LM∆ActA-infected mothers failed to produce IL-
12p40 (Table 4). GNP-GAPDH1-22 nanovaccination during 
pregnancy also prevented other manifestations of severe 
forms of listeriosis such as stillbirth or brain disease, since 
vaccinated mothers challenged with LMWT gave birth to 8 
± 0.1 pups, similar to NV and NI mothers (Figure 5C) and 
showed normal cerebral cellularity and vascularization 
(Figure 5C). Histological examination and anti-CD31 
immunostaining of P4 neonates born to GNP-GAPDH1-
22-vaccinated mothers challenged with LM
WT; indicated 
normal skin and mature lungs, spleen and stomach 
(Figure 5C) and corrected vascularization of these organs, 
indicating prevention of development retardation. GNP-
GAPDH1-22 formulated with Advax, while showing 
listeriosis protection in brains (2-3 CFU/mL), failed to 
reduce liver LMWT (400 CFU/ml) and produced anti-
GAPDH1-22 antibodies, while produced high IL-10 levels 
(Table 4). 
DISCUSSION
Brain morbidities reported in neonatal listeriosis 
implied meningitis, brain abscesses, diffused skin lesions 
and rash, fever or lethargy [2, 9, 33-36]. We found that 
neonatal listeriosis in our health institutions, HUMV and 
HUD, represented 28% of all listeriosis cases but with 
high mortality rates of 50%, urging the development of 
safe vaccines to protect pregnant women at high risk of 
listeriosis and to prevent neonatal brain illness. The major 
Table 4: Immune efficiency of GNP-GAPDH1-22 vaccination of pregnant mothers.
CONDITION OF PREGNANT MICEa
Cytokine pattern of MGa anti-GAPDH1-22 
antibodiesbTNF-α IL-6a IL-12p40 IL-10 TNF-α/IL-6
CONTROL-NI 3.3± 0.1 3.2 ± .01 1.0±0.1 1.3 ±0.2 1.06 ± 0.1 0.15 ± 0.1
NV-LMWT 1190±0.9 105± 0.2 2.0±0.1 15.8 ±0.2 11.3 ± 0.7 0.41 ± 0.2
NV-LM∆ActA 25 ± 0.1 13 ± 0.6 1.9±0.1 5.7 ±0.1 1.9 ± 0.2 0.31 ± 0.1
GNP-GAPDH1-22/DIO-1+ LM
WT 80 ± 0.1 3.4 ± 0.1 43±0.1 1.3 ±0.1 23.5 ± 0.3 1.85 ± 0.2
GNP-GAPDH1-22/DIO-1 + NI 20 ± 0.1 3.0 ± 0.1 13±0.1 1.3 ±0.1 6.6 ± 0.1 0.89 ± 0.2
GNP-GAPDH1-22/Advax+ LM
WT 81 ± 0.1 7.9 ± 0.2 32 ± 0.1 12.1 ± 0.1 10.2 ± 0.2 0.45 ± 0.1
GNP-GAPDH1-22/Advax+ NI 18 ± 0-1 7.1 ± 0.1 10 ± 0.1 10-2 ± 0.2 2.5 ± 0.1 0.11 ± 0.1
aE16 pregnant mothers were NV and NI (CONTROL-NI), NV and infected with LMWT (NV-LMWT) or LM∆ActA (NV-LM∆ActA) 
or vaccinated with GNP-GAPDH1–22 nanovaccines (formulated with DIO-1 or Advax at 10 µg/mL) at E9 and challenged with 
LMWT at E16 (GNP-GAPDH1–22 + LM
WT). aPro-inflammatory pattern of microglial cells from P4 neonates born to mothers 
inoculated as above. Levels of pro-inflammatory cytokines were analysed by flow cytometry. Microglial cells were cultured in 
vitro for 2 h and culture supernatants collected. All supernatants were filtered before storage at −80°C to remove bacteria from 
cytokine measurements. Results are expressed as the mean ± SD concentration (pg/mL) from three independent experiments. 
ANOVA was applied to cytokine results (P < 0.05). bSera of mothers inoculated with the different LM strains were examined 
for anti-GAPDH1–22 antibodies by peptide ELISA. Results are presented as mean ± SD OD units from triplicate experiments 
(P < 0.05).
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Figure 5: Effect of pregnancy vaccination with GNP-GADPH1-22 nanovaccines formulated with DIO-1 in neonatal 
listeriosis. A. P4 neonates born to NV (NV-LMWT), LM∆ActA-vaccinated (LM∆ActA) or GNP-GAPDH1-22-vaccinated mothers for 7 
days. All groups were challenged with LMWT for 3 days. P4 neonates and mothers were killed and livers and brains of P4 neonates were 
homogenized to determine number of viable bacteria in brain-heart infusion agar plates. Results are expressed as the mean ± SD CFU 
(P ≤ 0.05). B. Left plot corresponds to clinical tests performed in P4 neonates born to GNP-GAPDH1-22-vaccinated mothers challenged 
with LMWT (GNP-GAPDH1-22), NV and challenged with LM
WT (NV) or control NI pregnant mothers (control-NI): movement test, skin 
test, length, weight and metrics were determined. Results are the mean ± SD of three different experiments. Bars, 0.1 ± 0.01 cm*, 0.5-1 
melanoblasts/mm of skin**. Right plot corresponds to isolated microglia of P4 neonates born to control-NI, NV or GNP-GAPDH1-22 
mothers, respectively and stained for annexin V-APC and 7-ADD. Results are expressed as the percentages of late apoptotic cells (black 
bars correspond to 7-ADD+ annexin V+) and the percentages of early apoptotic cells (white bars correspond to annexin V+ 7-ADD− cells) 
(mean ± SD) (P ≤ 0.05). C. Left images correspond to P0 neonates born to control-NI, NV or GNP-GAPDH1-22 mothers; the two latter, 
challenged with LMWT. Right images show HE staining of skin and lungs from P4 neonates and immunohistochemical staining of CD31 
marker in brain and lung sections. 
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morbidities we observed in our neonatal listeriosis cases 
were foetal death (patient HUD003 and second twin of 
patient HUD004) and severe meningitis in a premature 
neonate that was treated successfully with ampicillin 
(neonate HUD008 of patient HUD007) [9]. The incidence 
of listeriosis has increased in Europe since 2008 and 
especially in Northern Spain with two outbreaks, and 
current incidence rates of 1.71-1.86 cases per 100,000 
inhabitants compared to 0.56 incidence rates before 2008 
[1, 5, 9]. 
Therefore, vaccines can decrease incidence of 
listeriosis and increase immunocompetency in pregnant 
women. To prepare effective vaccines, we must identify 
immune biomarkers of good prognosis and the cells and 
mechanisms responsible for brain disease. Two immune 
biomarkers seem to be relevant in listeriosis, high titres 
of anti-GAPDH1-22 antibodies that indicate the ability 
of mothers with neonatal listeriosis to elicit potent LM-
specific immune responses, and high Th1/Th2 ratios that 
prevent bacterial dissemination [9]. In this regard, all our 
patients developing neonatal listeriosis, had high titres 
of anti-GAPDH1-22 antibodies but low TNF-α/IL-6 ratios, 
confirming our efforts to formulate vaccines that increase 
Th1/Th2 ratios. Synthetic nanovaccines formulated with 
GNPs coupled to LM epitopes such as GNP-LLO91-99 or 
GNP-GAPDH1-22 have been tested successfully in systemic 
experimental listeriosis in adults [39, 41]. Since patients 
with listeriosis have failed to produce anti-LLO antibodies 
[9], we focused on GNP-GAPDH1-22 nanovaccines, 
selecting the adjuvant DIO-1 for the vaccine formulation, 
because it induces IL-12p40 and fails to produce IL-10 
[40], avoiding disproportionate inflammation in the brain. 
To explore the cells and mechanisms responsible 
for brain disease, we established a neonatal experimental 
listeriosis model by inoculating pregnant mice with 
pathogenic LMWT at late pregnancy (E16). While not 
exactly similar, this experimental model of neonatal 
listeriosis mimics several human clinical symptoms 
of listeriosis [5, 9, 33-36, 42-44] and appears to retard 
normal foetal development (this study). In this regard, 
the threefold reduction in the number of neonates born to 
LMWT-infected mothers resembled spontaneous abortion 
(patient HUD003) or stillbirth (second born twin of patient 
HUD004), which were the most severe morbidities of 
neonatal listeriosis. Similarly, the enlarged heads, softer 
cranial covering and low number of neuronal bodies, are 
related with brain dysfunction and explained the lacked of 
coordinated movements, resembling severe brain diseases 
reported in neonates not treated with antibiotics [1, 2, 
33]. Moreover, the lack of melanoblasts in the hair bulbs 
and a thinner epidermis with a delicate stratum corneum, 
are justified with a retard in the embryonic development 
at E16 stage induced by LM infection. At E16 stage, 
normally neural crest derivatives such as neurons, glial 
cells or melanoblasts start migration from the neural tube 
to brains or skin, respectively [45]. It is possible that LM 
infection causes impairment of melanoblast migration at 
this stage, since LM targets to melanocytes and induces 
apoptosis [46]. Moreover, other immature features, such 
as non-distended stomach, collapsed lung and reduction 
of blood vessels in the lungs and brain, are consistent with 
arterial ischaemic stroke and foetal bradycardia in early 
postnatal death [3, 36, 44]. These immaturities, together 
with the lack of spleen, retarded cerebellar formation and 
melanocyte migration to the skin in experimental neonatal 
listeriosis, which suggests severe delayed development, 
but also reduction of innate immune responses. Reduced 
innate immune responses explain dissemination of the 
pathogen in the liver and brain. Patients with neonatal 
listeriosis frequently presented with bacteraemia (HUD004 
and HUD003), suggesting penetration of the blood-brain 
barrier and LM replication in the subarachnoid space, 
causing meningitis (patient HUD008) and cerebritis [33]. 
Neonatal meningitis caused by group B Streptococcus is 
associated with recruitment of microglia and induction of 
non-classical apoptosis [22, 25]. Similarly, microglia are 
the target cells in brains of mice with neonatal listeriosis, 
inducing a TNF-α-mediated transcriptional program 
of cell suicide that up-regulates early macrophage 
signaling via tlr1, tlr2, tnf-α, nfkB, cd14 and mapk1 
genes with low induction of ccl3 and ccl5 chemokine 
genes, which suggests poor recruitment of monocytes to 
the brain compared to during systemic listeriosis [47]. 
This transcriptional program also down-regulates pro-
inflammatory genes involved in macrophage activation 
and antigen presentation, such as pi3kcg, h2-k1, smpd1, 
scarb2 and rab14 genes. This transcriptional program 
is consistent with the cell surface apoptotic phenotype 
of microglia, CD11blowMHC-IlowCD40lowF4/80highMHC-
IIhighAnnVhighCD86− [24] that appears to be regulated by 
the bacterial actA gene and not the classical hly gene that 
induces apoptosis in most phagocytes [27, 28]. This TNF-
α-mediated apoptotic transcriptional program appears to 
be a mechanism to limit over-activation of innate immune 
responses, common to other bacteria inducing meningitis 
[22, 25] and consistent with high production of Th2 anti-
inflammatory cytokines, IL-6 and IL-10, but low levels 
of Th1 cytokines such as IL-1β and IFN. Therefore, we 
consider this apoptotic pattern in neonatal mice as a TNF-
IL-6 producing MG. The high numbers of CFUs detected 
in microglia of P4 neonates born to LMWT-infected 
mothers, verified the failure of microglial microbicidal 
mechanisms previously suggested in vitro [19], and 
therefore, microglial dysfunction. Microglial dysfunction 
in neonatal listeriosis explains brain disease such as motor 
impairment or lethargy. 
Evaluation of two vaccine formulations, GNP-
GAPDH1-22/DIO-1 and GNP-GAPDH1-22/Advax, 
in pregnant female mice before infection with LM, 
highlighted that DIO-1 adjuvant was superior to prevent 
neonatal listeriosis and avoid dissemination of the 
pathogen to the brain or liver, but also to avert brain 
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disease associated with microglial failure. Neonates 
born to GNP-GAPDH1-22 nanovaccinated mothers 
showed normal numbers at birth with healthy conditions, 
coordinated movements, normal brain cellularity and 
vascularization, and no induction of apoptosis in microglia 
that produced high levels of IL-12p40 and TNF-α. These 
nanovaccines formulated with DIO-1, also induced high 
titres of anti-GAPDH1-22 antibodies in sera of vaccinated 
mothers, inducing LM-specific immunity and memory. 
We explained this broadened action of nanovaccines 
formulated with DIO-1 by implementing TLR2 signalling 
in different innate immune cells that elicit listeriosis-
protective Th1 immune responses [40, 47-49]. The low 
production of anti-inflammatory cytokines IL-10 and IL-6 
using DIO-1 as adjuvant prevented bacterial dissemination 
and induction of acute responses in the brain, preserving 
its integrity. Vaccine formulations with Advax or LM∆ActA 
mutants failed to produce anti-GAPDH1-22 antibodies, 
reduced CFUs in the liver and induced IL-10 production, 
confirming GNP-GAPDH1-22 nanovaccine formulations 
with DIO-1 were superior. Nevertheless, Advax-
formulated nanovaccines conferred significant listeriosis 
protection, while LM∆ActA mutants did not.
We conclude that GNP-GAPDH1-22 nanovaccines 
formulated with a TLR2/4 targeted adjuvant, DIO-1, 
can be administered during pregnancy as they elicit 
Th1 protective immune responses and strong innate and 
specific immune responses. Their nanoscale formulation 
allows them to cross the placental barrier and induce a 
Th1 response in neonates that prevents brain and liver 




We used L. monocytogenes strains EGD (ATCC) and 
10403S (LMWT) and LM∆LLO and LM∆ActA mutants derived 
from 10403S strain (D.A. Portnoy, Berkley University, 
CA, USA), GFP-LMWT and GFP-LM∆ActA derived from 
EGD strain (M. Lecuit, Pasteur Institute, Paris, France) 
[38], and GFP-LM∆LLO derived from 10403S strain (D.E. 
Higgins, Harvard Medical School, Boston, MA, USA). 
LLO189-201 and GAPDH1-22 peptides were synthesized 
at Centro Nacional de Biotecnología (CSIC, Madrid, 
Spain) followed by HPLC and mass spectrometry using a 
MALDI-TOF Reflex IV spectrometer. Peptide purity was 
≥95% after HPLC.
Animals
We used C57BL/6 mice from our animal facilities 
at the University of Cantabria at 8-12 weeks old. Three 
female and one male mice were mated and assessed for 
the appearance of vaginal plugs denoting first embryonic 
day of pregnancy. 
Patients and listeriosis cases
Listeriosis was confirmed in the foetus or stillborn 
or newborn infant according to the Commission 
Decision of 28/IV/2008 and classified as listeriosis at 
the Microbiology Department of Hospital Universitario 
Donostia (San Sebastian, Spain) during 2013-2015. 
In total, 13 human listeriosis episodes were detected in 
Gipuzkoa, which has an annual incidence of 1.86 cases 
per 100,000 inhabitants. Bacteria were recovered from 
blood in all cases. Description of patients and clinical 
manifestations is shown in Suuplementary Table S2. All 
patients participated in the study voluntarily and they 
gave signed informed consent at the time of physician 
consultation and received an information document about 
the study. Patients could revoke the informed consent at 
any time.
Nanoparticles and adjuvants
To obtain GNPs carrying GAPDH peptide (GNP-
GAPDH1-22), an aqueous solution of tetrachloroauric acid 
(Strem Chemicals, Newburyport, MA, USA) (0.025 M, 1 
eq.) was added to a mixture of glucose (90%) and GAPDH 
peptide (10%) with thiol ending ligands (0.012 M, 6 eq.) in 
methanol/water/acetic acid (3:3:1). The detailed procedure 
has been reported previously [39]. The size distribution 
of the GNPs was evaluated from several transmission 
electron micrographs (JEM-2100F; Jeol, Tokyo, Japan), 
with an average diameter and number of gold atoms of 
2.1 ± 0.5 nm. The presence of glucose and peptide ligands 
was confirmed by 1H NMR and the amount of GAPDH 
peptide on the GNPs was determined by quantitative NMR 
in a Bruker AVANCE 500 MHz spectrometer (Bruker, 
Billerica, MA, USA). GNPs (0.234 mg) were dispersed in 
99.9% D2O (200 μL) and 80 μl of this solution was added 
to 40 μl 0.05% 3-(trimethylsilyl)propionic-2,2,3,3-d4 
acid sodium salt solution in D2O as an internal standard. 
Peptide loading was 10.6 μg/0.234 mg GNPs and GNP-
GAPDH1-22 and their stability in dendritic cells has been 
described previously [35]. DIO-1 is a TLR2/4 targeted 
molecule that can be used as an adjuvant [40] and Advax 
is an inulin formulated adjuvant [41].
In vivo virulence of clinical LM isolates
C57BL/6 female mice were inoculated i.v. with 
100 µL suspension of each clinical isolate in saline (5000 
CFU/mice). At 72 h post-inoculation, mice were killed 
and spleens recovered and homogenized, and viable 
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bacteria were determined on blood agar plates. Results are 
expressed as the mean ± SD of CFU/mL. All data were 
gathered in triplicate and we performed three independent 
experiments.
In vivo model of neonatal listeriosis
Pregnant C57BL/6 female mice (n = 5) were 
inoculated intravenously (i.v) at 16 days of gestation 
(E16) via the lateral tail vain with 100 µL of a GFP-
LMWT, GFP-LM∆LLO, GFP-LM∆ActA, LMWT, LM∆LLO or 
LM∆ActA bacterial suspensions in saline (3000 CFU/mL) 
(LMWT, LM∆LLO or LM∆ActA infected mothers) or inoculated 
with 100 µL of saline (non-infected (NI) mothers) (n = 
5). All animals were examined daily. Three P4 neonates 
born to NI, LM∆LLO or LM∆ActA mothers and the two P4 
survivors born to LMWT infected mothers, were killed to 
obtain the cerebellum for preparation of mixed microglia 
and subsequent isolation of primary microglial cultures 
for CFU quantification, cell surface markers analysis by 
FACS, and cytokine quantification. LMWT-infected and 
NI mothers were bled for cytokine and anti-GAPDH1-22 
antibody analysis and killed to obtain spleens and livers 
for CFU quantification and analysis of cell populations 
by FACS. Results were expressed as CFU/mL in spleens 
and livers and CFU/mL in microglial cultures ± SD of 
triplicates. 
Clinical tests in mice
Clinical tests were performed at P4 on all pups born 
to mothers infected or not with different bacterial strains. 
Metric tests of health conditions and units were as follows: 
weight (milligrams × 10), length (mm), movement assay 
placing pups in a 10-cm metric paper and recording the 
movement after 5 min (cm) and skin test, counting the 
number of black bulbs under a magnifying glass in 1 mm 
of skin, and skin was observed for general appearance 
as wrinkled or flattered. All results are the mean ± SD of 
three different experiments.
Mixed microglial cell cultures and purified 
primary microglia
Microglial cultures and detailed procedures for 
obtaining mixed microglial cultures and purified primary 
microglia have been reported previously [19]. 
Prenatal vaccination
Pregnant C57BL/6 female mice were vaccinated 
(n = 5) or not (n = 5) at day 9 of gestation (E9) via the 
lateral tail vain with GNP-GAPDH1-22 formulated with 
DIO-1 adjuvant (5 µg nanoparticles and 2 µg DIO-1). At 
16 days of gestation (E16) all mice, were inoculated i.v 
with 100 µL of a LMWT or LM∆ActA bacterial suspension 
in saline (1 × 104 CFU/mL) (NV-LMWT or NV-LM∆ActA 
infected mothers). All animals were examined daily. At 
E20 we detected 3 ± 0.5 pups born to LMWT infected 
mothers, 4 ± 0.5 pups born to LM∆ActA infected mothers 
and NV, while 8 ± 0.1 pups were born to control and GNP-
GAPDH1-22 vaccinated mice, challenged or not with LM
WT 
(or LM∆ActA) (P ≤ 0.05). Results were the mean ± SD of 
three independent experiments. Four days after birth, P4 
postnatal pups born to NV or GNP-GAPDH1-22-vaccinated 
and LMWT- (or LM∆ActA)-infected mothers were killed to 
quantify viable CFU/mL in whole brains and livers. Other 
P4 neonates were used for preparation of microglial 
cultures and measurement of cytokines and viable CFU/
mL in these cells. 
Immunohistochemistry
Neonates were killed on day 4 after birth (P4) and 
were immersed in 4% formalin for cryopreservation of 
complete bodies. Most frequently affected organs (brain, 
skin, spleen, lungs and blood vessels) were resected, 
sectioned and fixed by immersion in 4% formaldehyde 
for 24 h. Organs were embedded in paraffin and cut at 
3-µm thickness for histological analysis. Different sections 
(stained with hematoxylin and eosin; HE) of each organ 
were analysed by two independent pathologists. For 
immunohistochemical analysis, EnVision technology 
(Dako) was applied. Samples were boiled in target 
retrieval solution buffer as described previously [35]. 
Sections were incubated with ready-to-use primary 
monoclonal antibody (Dako) against CD31 to explore 
vascularized endothelia in neonatal organs. Antigen was 
visualized using biotinylated antibody and streptavidin 
conjugated with horseradish peroxidase (EnVision Mouse 
HRP; Dako). Diaminobenzidine (Dako) was used as the 
chromogen.
Fluorescence label by confocal microscopy
Cells used for confocal microscopy were fixed in 3% 
paraformaldehyde. Fluorescence labelling and confocal 
microscopy were performed as previously described [10, 
19].
Flow cytometry analysis
Microglia purified from P4 neonates were cultured 
in vitro and cultured supernatants filtered and stored 
at −80°C before cytokine analysis using a CBA pro-
inflammatory kit (BD Biosciences, NJ, USA) [10, 19]. 
Samples were analysed in triplicate and results are shown 
as the mean ± SD of three separate experiments. 
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Microglia were infected or not with different LM 
strains for 20 min (LMWT, LM∆LLO or LM∆ActA). We isolated 
RNA and performed differential microarray analysis using 
the Affymetrix GeneChip MOE430A2.0 that evaluates 
22,626 mouse genes [19]. The results of microarray 
analysis were deposited in NCBI Gene Expression 
Omnibus and accessible through GEO Series accession 
number GSE32505 (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE32505). Results of the differential 
microarrays are expressed as signal log ratio (SLR). All 
final values were subtracted from basal controls values 
that corresponded to NI cells (detailed in Supplementary 
Information).
ELISA for LLO189-201 and GAPDH1-22 peptides
We obtained sera from NV LMWT-infected, NV 
LM∆ActA-infected, NV NI, GNP-GAPDH1-22 vaccinated 
LMWT-infected and GNP-GAPDH1-22 vaccinated NI 
pregnant mice. Sera were also obtained from listeriosis 
patients. Peptide ELISA was performed as described 
previously [12, 39]. LLO189-201 and GAPDH1-22 peptides 
were prepared at 50 μg/mL in coating buffer (50 nM of 
Na2CO3 at pH 9.7) and used to coat Nunc MaxiSorp plates 
overnight at 4 °C. Plates were blocked with 1% BSA 
in PBS at room temperature for 30 min and mouse sera 
were diluted 1/200 in PBS/0.5% BSA and incubated for 
1 h at room temperature. IgM was detected with a goat 
anti-mouse IgM conjugated with horseradish peroxidase 
or goat anti-juman IgM conjugated with horseradish 
peroxidase (0.8 μg/mL) and enzymatic reactions 
developed with tetramethyl benzidine in citric/acetate 
buffer and H2O2. Reactions were stopped with 50 μL 
H2SO4 (0.8 M) and absorbance was measured at 450 nm 
in the ELISA reader. Results were expressed as mean ± SD 
absorbance units from triplicate experiments.
Statistical analysis
For statistical analysis, the Student’s t test was 
applied. P≤0.05 was considered significant using 
GraphPad for graphic presentation. ANOVA was used for 
cytokine analysis (BD Biosciences, San Jose, CA).
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